The company's principal activities are to develop, manufacture and market proprietary orthopedic products. These products are designed to promote the healing of musculoskeletal tissue, with particular emphasis on fracture healing and spinal repair. The products are designed to enhance the healing of diseased, damaged, degenerated or recently repaired musculoskeletal tissue. The products improve the clinical outcomes and cost-effectiveness of orthopedic procedures that are characterized by compromised healing, high-cost, potential for complication and long recuperation time. The product line includes bone growth stimulation and fracture fixation devices. These products are sold primarily through the company's direct sales force supplemented by regional distributors. On Nov 26, 2003 the group sold bone growth stimulation device business to dj orthopedics, llc. It is in the process of developing and testing our chrysalin(R) product platform.
